Science and Technology › Health and disease
हिन्दी — Read in HindiDrugs, diagnostics and medical technology
Drug approval and trials, the pharmacopoeia, substandard medicines, generics, prices, devices and pharmacovigilance. It serves GS3 answers on science and technology in health.
Foundation note: Who regulates medicines in India, and the drug schedules
Showing 3 of 9 articles, those that changed from 1 July to 30 September 2026.Show all
Central licensing of cell and gene therapies
Copy link to Central licensing of cell and gene therapiesPrelims and Mains
Stem cell products, gene therapies and xenografts are licensed jointly by the central and State drug regulators under the Drugs Rules, 1945, as vaccines and recombinant medicines already are.
- This closes the route by which clinics sold unproven stem cell cures.
What changed
3 Jul 2026New
- The Drugs Rules, 1945 were amended to bring stem cell products, gene therapies and xenografts under joint central and state licensing, as vaccines and recombinant DNA medicines already are.
- The amendment approves no therapy. Its practical target is clinics selling unproven stem cell cures.
- It covers CAR-T therapy, in which a patient's own T cells are engineered to attack cancer, and animal tissue products such as heart valves.
The Indian Express, 3 Jul 2026: Stem cell products, gene therapies and xenografts brought under central licensing (opens in a new tab) · PIB, 2 Jul 2026: Centre Expands Centrally License Approving Authority (CLAA) Framework to Include Cell and Stem Cell-derived Products, Gene Therapeutics and Xenografts (opens in a new tab) · The Hindu, 4 Jul 2026: Central licensing net to cover stem cell, gene therapies (opens in a new tab)
Drones for tuberculosis samples
Copy link to Drones for tuberculosis samplesPrelims and Mains
i-DRONE is the Indian Council of Medical Research's programme for carrying medical samples and supplies by drone, tested for tuberculosis sputum samples in Telangana.
What changed
12 Jul 2026BriefA study under the i-DRONE initiative in Yadadri Bhuvanagiri district of Telangana flew sputum samples from health centres to laboratories. Diagnosis time fell from 15 days to 5, and the patient's average cost fell too. The Hindu, 12 Jul 2026: Drones move TB samples, cut diagnosis costs from ₹9,451 to ₹91 in new ICMR trial (opens in a new tab) · PIB, 16 Jul 2026: Research under the ICMR’s i-DRONE initiative demonstrates the potential of drone technology to strengthen access to TB diagnostic services in difficult-to-reach areas (opens in a new tab)
Rare diseases and orphan drugs
Copy link to Rare diseases and orphan drugsPrelims and Mains
An orphan drug is a medicine for a rare disease, long neglected by drug makers because the market for it is small.
- Government support for a patient with a rare disease is capped at ₹50 lakh, and there is a government crowdfunding platform for patients.
- The drug regulator may waive a local clinical trial for a drug already approved in certain other countries.
What changed
29 Sep 2026New
- India has reported about 1,000 rare genetic disorders, and drugs exist for only about 5 per cent of rare diseases.
Mains: incentives for manufacture, advance purchase commitments and pricing that shares benefits could make India a base for affordable orphan drugs.